# A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

> **NCT00484289** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 217 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT00484289
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2013-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484289, "A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00484289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*